Quipt Home Medical Corp T.QIPT

QIPT Financial Forecast - Annual -2024/2028

[sollmg]

Financial Forecast

AnnualQuarterly

Export

Revenue This Year

267.54M

Increased by20.65%

from 221.74M

Revenue Next Year

289.05M

Increased by8.04%

from 267.54M

EPS This Year

-0.03

from -0.07

EPS Next Year

0.11

from -0.03

Year	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028
Revenue	80.97M	72.64M	102.35M	139.86M	221.74M	267.54M	289.05M	340.95M	505.28M	581.09M
Revenue Growth	-	-10.29%	40.90%	36.65%	58.54%	20.65%	8.04%	17.96%	48.20%	15.00%
EPS	-0.36	-0.20	-0.20	0.13	-0.07	-0.03	0.11	0.38	1.24	1.60
EPS Growth	-	-	-	-	-	-	-	252.20%	225.18%	28.86%
Forward PE	-	-	-	-	-	-	30.43	8.64	2.66	2.06
No. Analysts	-	-	-	-	-	9	7	5	3	3

[mjh9413]

Not long but keep watching this one out of intrigue more than anything else. Find the analyst ratings 'unreliable.' from $3.53 to about $10 done in May by 6 analysts (I find the first 4 letters generall speak a lot to what these people come up with, particularly when they are involved in financings, which all of them I believe were in that 04/23 bought deal at $7,75, Seems like they

[westcoastlogger]

Its a growth stock with a current DOJ investigation hanging over its head because someone forgot to dot an i or cross a t on a purchase agreement. When that will be over is anyones guess and we would be positive EPS if we weren't spending money on growing the company. Or we may be bought out next Tuesday for all anyone knows. Thats why I'm longer than a Norwegian ski here.

[KarlGibbons]

QIPT is not a growth company.  They had negative growth last Q sequentially.  They will be flattish at best going forward without buying growth via acquisitions. The DOJ investigation is not someone forgetting to "dot an i or cross a t"....its very serious.  They don't pick up these cases without serious belief of wrongdoing, usually initiated by a whistleblower.

[gibbonsj]

Karl I read your posts because we may share common ancestry but there's a lot of people in my family who are full of it. You would probably get along well with them.

[Moemoney42]

Exactly Karl.. not to mention, management stated they won't be cash flow positive for 2 years.. a growth company.. LMAO..!!  Is this the chart of a "growth company"..???

[lscfa]

Stop lying. Co. is cash flow positive now and never said it would take 2 years. What you reference is eps which is distorted with a lot of accounting BS like amort of intangibles.    Michael Freeman  I think we could squeeze just one more in one big shift that we've noticed from ‘22 to ‘23 is the shift from sort of positive to negative EPS. And I wonder if you provide

[lscfa]

Michael Freeman I think we could squeeze just one more in one big shift that we've noticed from ‘22 to ‘23 is the shift from sort of positive to negative EPS. And I wonder if you provide sort of a rough outlook for 2024 in respect to earnings? Hardik Mehta If you know, company year-over-year you'll see some of the few contributors for the positive cashflow, or not cashflow, my bad

[lscfa]

Accounting net income is a lousy metric, distorted by all sorts of BS accounting conventions. Focus on cash flow.     eps $US March June Sept December 2024 ($0.03)      

[Moemoney42]

"Co. is cash flow positive now and never said it would take 2 years. What you reference is eps which is distorted with a lot of accounting BS like amort of intangibles." Well I stand corrected and re-iterate that even EPS metrics prove my point.. now for the TSX to have a whopping 1400 shares traded in over 3 hrs today confirms my point.. its not a "growth" company by any

[HatrikSeLaine]

Agreed.  Why are we not seeing NCIB volume these past few weeks.  Time to can the next Comp package in Q1 2025.  Seriously, these idiots are doing nothing to earn their fat pay envelopes.

[Tropicalsun]

Any company that has a current NCIB, is only required to report the number of shares purchased under the program on a quarterly bases.

[HatrikSeLaine]

We are aware of this fact, but the paultry daily volume we're seeing in the past few weeks means they are not currently active with the NCIB.  We should be seeing daily maximums allowed by the NCIB at these ridiculously low prices.  It speaks volumes as to how they're sitting on their hands at this particular time.   Do they feel the share price is yet too high to start

[lscfa]

The flat growth last qtr was due to a 1 time decrease to reimbursement rates which will not repeat.  Co. guided 8% to 10% organic growth going forward.  

[KarlGibbons]

It wasn't flat, it was a decline.  It was due not only due to reimbursement changes but also patient losses to competitors as highlighted in the PR.

[lscfa]

Liar. Mgmt guided 8%-10% organic growth going forward. It's in the NR.  

[KarlGibbons]

Mgmt got on the 1st quarter conference call (halfway thru Q2) and talked of 8-10% organic growth...then showed a DECLINE when reporting Q2.  They made no mention of the capitation customer loss on the Q1 call...and they disclosed on the Q2 call that the organic growth assumptions assumed a reversal of the rural 75/25 expiry...who does that?  every other player AHCO, VMD etc incorporated

[gibbonsj]

Clearly you're hanging around for something. Too risky to short at this point so what is it?

[KarlGibbons]

Why is it a risky short?  its been going down for 3.5 years!  why would that change.  It's actually been a very risky long! and poor performing.  I see nothing here to get excited about.  DOJ & SEC investigations, product disruption, shaky mgmt and board, no investor interest etc...what do you see? Given the revaluation of the DME sleep businesses, I suspect major

[lscfa]

Stop misleading people. Co. is entering diabetes segment and cross selling CGMs and supplies at no extra cost to SG&A. 

[EdinColorado]

Schwab has rated QIPT as an "A" for a long time, during which it has lost over 30% of its value. Healthstream also garners an "A" rating, but its value has risen.

[EdinColorado]

Schwab has rated QIPT as an @A@ for a long time, during which it has lost over 30% of its value. Healthstream also garners an @A@ rating, but its value has risen.

[sollmg]

    505 mil in 2027, 581 mil in 2028

[lscfa]

Raymond James forecast   RJ forecast 2022 2023 2024 2025 2026 2027 revenue 139.9 221.3 280.5 347.8 424.3 509.2